USA flag logo/image

An Official Website of the United States Government

Depot calcineurin inhibitors to prevent graft rejection

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85262
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AI069674
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AURITEC PHARMACEUTICALS, INC.
1512 11th Street SANTA MONICA, CA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: Depot calcineurin inhibitors to prevent graft rejection
Agency: HHS
Contract: 2R44AI069674-02
Award Amount: $1,330,823.00
 

Abstract:

DESCRIPTION (provided by applicant): The long term goal of this research is to reduce toxicity and graft rejection due to dosing problems with the calcineurin inhibitors by developing a sustained release subcutaneous injectable formulation of a calcineurin inhibitor. Substantial inter-and intra-patient variability of the calcineurin inhibitors cyclosporine A (CsA) and tacrolimus (Tac) means that even frequent drug monitoring cannot eradicate rejection due to sub- therapeutic troughs or toxicity due to highe r than necessary peak levels. In addition, non-adherence with the daily oral dosing regimen is a major cause of graft failure especially in adolescent patients. Pharmacokinetic modeling suggests that periodic subcutaneous dosing can reduce or eliminate man y of these problems. The potency and the long elimination half-lives of CsA or Tac make them suitable for depot formulation. In Phase 1 we developed sustained release formulations for cyclosporine and tacrolimus, measured there in vitro dissolution and dem onstrated tolerability and sustained release in an in vivo model. We have decided to focus on the development of sustained release CsA in this Phase 2 proposal because it was easier to crystallize and demonstrated superior pharmacokinetics when tested in r ats. In addition, because the patents for the parent drug have expired for CsA (and remain in effect for Tac until 2013), we believe that there will be more flexibility in partnering for further development. The specific aims of this Phase 2 proposal are t o: 1, optimize the parameters of the sustained release CsA formulation; 2, manufacture clinical lots of the optimized formulation under GMP; and 3, perform animal toxicity and pharmacokinetic studies in rats. The team of investigators is expert in polymer chemistry, pharmacokinetics, and drug development and transplantation biology. We have experience in all aspects of the drug development process, from concept to approval and marketing. The PI led the team that developed two other FDA approved drug deliver y systems. More than 50,000 transplants requiring immunosupression are performed annually in the largest 7 markets (US, Japan, Germany, Britain, Canada, France, Italy), and the market for immunosuppressive drugs is estimated at 2.9 Billion annually (2007) . We recognize that a sustained release formulation of cyclosporine or tacrolimus will only ever be used in a small percentage of patients. However, each 1% of this market represents 29 million in market opportunity. Our business model is to license to 'b ig pharma' at the earliest opportunity. Because the likelihood of success is high (we know the drugs work, we are only changing the delivery route), because the costs of clinical trials can be reclaimed under the tax provisions of the Orphan Drug Act, and because we have done this kind of deal before, we are confident that the successful completion of this work will culminate in a commercial product of significant medical utility. PUBLIC HEALTH RELEVANCE: The leading cause of failure in heart, liver, and kidney transplants in children is that kids just stop taking their medicines. The beatific 8 year old who promises never to miss a day, is soon the spiky haired 14 year old who knows better about everything. Missing just a few days can be fatal. We ha ve developed an injectable formulation for the immunosuppressive cyclosporine which has the potential to be delivered weekly, or even less frequently. Because of the long half life of cyclosporine, missing our injection by a day or two is not likely to be a serious problem. Parents can monitor a weekly or semi-monthly schedule much more carefully than daily dosing. An additional benefit of this delivery system is that peak levels that lead to toxicity are blunted, and trough levels, which can lead to failur e, are less likely to occur. In Phase 1 we demonstrated proof of concept in an animal model. In Phase 2 we propose to optimize the parameters of the delivery system, manufacture it according to FDA standards, and confirm its delivery profile and safety in further animal studies.

Principal Investigator:

Thomas J. Smith
6266605692
TSMITH@AURITEC.NET

Business Contact:

Thomas J. Smith
tsmith@auritecpharma.com
Small Business Information at Submission:

AURITEC PHARMACEUTICALS, INC.
AURITEC PHARMACEUTICALS, INC. 1434 6th Street, #3 Santa Monica, CA 90401

EIN/Tax ID: 841629188
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No